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The use of live Listeria-based vaccines carries serious difficulties when administrated
to immunocompromised individuals. However, cellular carriers have the advantage of
inducing multivalent innate immunity as well as cell-mediated immune responses,
constituting novel and secure vaccine strategies in listeriosis. Here, we compare
the protective efficacy of dendritic cells (DCs) and macrophages and their safety.
We examined the immune response of these vaccine vectors using two Listeria
antigens, listeriolysin O (LLO) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH),
and several epitopes such as the LLO peptides, LLO189−201 and LLO91−99 and the GAPDH
peptide, GAPDH1 22. We discarded macrophages as safe vaccine vectors because they−
show anti-Listeria protection but also high cytotoxicity. DCs loaded with GAPDH1−22
peptide conferred higher protection and security against listeriosis than the widely
explored LLO91 99 peptide. Anti-Listeria protection was related to the changes in DC−
maturation caused by these epitopes, with high production of interleukin-12 as well as
significant levels of other Th1 cytokines such as monocyte chemotactic protein-1, tumor
necrosis factor-α, and interferon-γ, and with the induction of GAPDH1−22-specific CD4+
and CD8+ immune responses. This is believed to be the first study to explore the use of
a novel GAPDH antigen as a potential DC-based vaccine candidate for listeriosis, whose
efficiency appears to highlight the relevance of vaccine designs containing multiple CD4+
and CD8+ epitopes.
Keywords: dendritic vaccines, Listeria monocytogenes, glyceraldehyde-3-phosphate-dehydrogenase
INTRODUCTION
Listeria monocytogenes is a Gram-positive pathogenic bacterium
that is widely used as a vector for vaccines against other
pathogens or in cancer therapy. However, because it is a
human pathogen, it may cause life-threatening infections such
as severe meningitis, encephalitis, and brain abscess in preg-
nant women, neonates, elderly people, and immunocompro-
mised individuals. Vaccination is one of the most successful
strategies to treat infectious diseases. However, in the case of lis-
teriosis, there is no vaccine available for high-risk groups such
as infants, pregnant women, or individuals with immunological
impairment.
Current studies of prophylactic vaccines against L. monocyto-
genes focus on three strategies: (i) the creation of live attenuated
pathogens able to access the cytosol and stimulate T cells, includ-
ing the vaccine vectors with metabolically active but non-viable
bacteria; (ii) the use of safe vectors with adjuvant properties able
to induce strong immune responses; and (iii) the use of sub-
unit vaccines containing bacterial antigens that might stimulate
specific immune responses (Sashinami et al., 2003; Starks et al.,
2004; Bruhn et al., 2007; Mohamed et al., 2012; Quispe-Tintaya
et al., 2013). There is not a single ideal vector that might be
considered safe for human trials, and the use of live vaccines in
individuals with any type of immunosuppression poses severe
difficulties. Safer vaccines such as subunit vaccines present the
disadvantage of requiring strong adjuvants to potentiate their
immune responses and these adjuvants might induce undesirable
side effects in tissues.
Dendritic cells (DCs) show promise for use as prophylac-
tic or therapeutic vaccine vectors in human trials (Martirosyan
et al., 2012; Palucka and Banchereau, 2013; Yu et al., 2013). DCs
play a major role in the development of cell-mediated immunity
because they link innate and adaptive immune responses. They
are powerful antigen-presenting cells (APCs) and have a distinct
ability to prime naïve T helper (Th) T lymphocytes and cytotoxic
T lymphocytes (CTLs). These features of DCs are responsible for
their immunostimulatory potential. In fact, they have been used
as cellular vaccines or adjuvants in immunotherapy against can-
cer or infections, such as listeriosis or aids (Pion et al., 2010; Kono
et al., 2012; Vacas-Cordoba et al., 2013).
Macrophages are also efficient APCs and crucial cells for
the innate and adaptive immune responses against listeriosis
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(Ziegler and Unanue, 1981; Portnoy et al., 2002; Pamer, 2004).
In fact, L. monocytogenes natural habitats are the monocytes
and macrophages, therefore, it seems likely that using these cells
loaded with the pathogen might secrete unique antigens and gen-
erate protective immune responses. Macrophages infected with
other bacteria such as Salmonella typhimurium orMycobacterium
tuberculosis have been successfully used as safe vaccines, con-
ferring good protection against these pathogens (Sharma and
Agrewala, 2004; Singh et al., 2011).
Murine L. monocytogenes infection is characterized by
the development of a protective T-cell-dependent immunity
mediated by both CD4 and CD8 T cells. Several T cell
immunodominant epitopes restricted by MHC-I molecules
have been reported such as the listeriolysin O (LLO) epi-
tope LLO91−99 and the p60 epitope p60217−225 (Sijts et al.,
1996; Pamer, 2004). Less information is available concern-
ing immunodominant CD4 epitopes restricted by MHC-II
molecules, because only LLO epitope LLO189−201 appears
as immunodominant and p60 epitope p60301−312 as sub-
dominant (Geginat et al., 2001). However, several other
L. monocytogenes virulence factors such as ActA, MLP or
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) (Álvarez-
Domínguez et al., 2008) appear to induce strong immune
responses, and therefore, they might contain putative epitopes
that confer protection against listeriosis. In this study, we exam-
ined the ability of a novel GAPDH peptide, GAPDH1−22 to
confer protection against listeriosis when incorporated into
macrophages or DCs as vaccine vectors. Our data showed
that macrophages infected with L. monocytogenes were unsafe
vaccine vectors, while GAPDH1−22-loaded DCs were safe
and more efficient vaccine vectors against listeriosis than
LLO91−99-loaded DCs.
METHODS
ANIMALS
We used C57BL/6mice from our animal facilities at the University
of Cantabria. Bone-marrow-derived macrophages (BMDMs)
or bone-marrow-derived DCs were obtained from femurs of
8–12-week-old female mice. BMDMs or DCs were cultured
at 2 × 106 cells/ml in six-well plates in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 20% fetal calf
serum (FCS), 1mM glutamine, 1mM non-essential amino acids,
50μg/ml gentamicin and 30μg/ml vancomycin (DMEM com-
plete medium) and 25 ng/ml macrophage colony-stimulating fac-
tor (M-CSF) for BMDMs or 25 ng/ml granulocyte–macrophage
colony-stimulating factor (GM-CSF). On Day 7, the cells were
harvested and analyzed by fluorescence-activated cell sorting
(FACS) to evaluate cell surface markers and appropriate differen-
tiation of BMDMs or DCs using the following markers: CD11b–
fluorescein isothiocyanate (FITC), CD11c–phycoerythrin (PE),
IAb–APC, F4/80–PE, CD80–FITC, and CD86–V450. Cells were
collected using cell scrapers for detaching adherent cells. In
certain samples we also used after detaching adherent cells
positive selection using anti-mouse CD11c-coated magnetic
beads and MACSTM separation columns (Miltenyi Biotech Inc.,
Auburn, CA) on Day 7 as previously described (Kono et al.,
2012).
BACTERIA
L. monocytogenes 10403S strain (LM-WT) and the hly-deficient
LM mutant (LM-LLO, DPL-2161 strain) were obtained from
D. A. Portnoy (University of California, Berkeley, CA, USA) and
green fluorescent protein (GFP)–L. monocytogenes variant of the
LM strain DH-L1039 (GFP-LM) was kindly provided by D. E.
Higgins (Harvard Medical School, Boston, MA, USA).
KINETIC INFECTION ASSAYS
Differentiated BMDMs or DCs were cultured in 96-well plates
at 1 × 106 cells/ml and infected with LM-WT or LM-LLO at
a ratio of 10: 1 (bacteria: cells) as previously reported for different
times (0, 4, 8, or 16 h) (Prada-Delgado et al., 2001). CFU ratios
are performed as reported and represented the ratio of CFU at
8 h to CFU at 0 h ± SD of triplicates (Prada-Delgado et al., 2001;
Carrasco-Marín et al., 2009).
POSTNUCLEAR SUPERNATANT ISOLATION AND
IMMUNOPRECIPITATION
BMDMs and DCs were non-infected (NI) or infected with
L. monocytogenes for 20min (10:1; bacterium: cell ratio)
and cells were homogenized in HBE buffer and postnuclear
supernatants (PNSs) were obtained as previously reported
(Álvarez-Domínguez and Stahl, 1999; Prada-Delgado et al.,
2001; Del Cerro-Vadillo et al., 2006; Carrasco-Marín et al.,
2009, 2011, 2012). Total membranes were pelleted from
thawed PNSs after 35,000 × g ultracentrifugation, as previ-
ously described (Carrasco-Marín et al., 2012). To detect LLO
bound to MHC class II molecules, total membranes from PNSs
were immunoprecipitated with mouse anti-IAb antibody (Y3P).
Immunoprecipitates were run onto SDS-PAGE, transferred to
nitrocellulose membranes and incubated with primary antibod-
ies, rabbit anti-LLO or rabbit anti-GAPDH1−22 and horseradish-
peroxidase-conjugated secondary antibodies.
CONFOCAL MICROSCOPY
BMDMs or DCs used for immunocytochemistry were cultured
in 24-well plates with coverslips at 1 × 106 cells/ml and infected
with GFP-LM at a ratio of 10: 1 (bacteria: cells) for 1 h. Cells were
washed with PBS and fixed in 3% paraformaldehyde. BMDMs or
DCs were labeled with biotinylated anti-IAb antibody (40F mon-
oclonal antibody) followed by TRICT-streptoavidin, CD11c–
PE or CD11b–PE, as previously described (Rodriguez-Del Rio
et al., 2011; Frande-Cabanes et al., 2014). All confocal proce-
dures with antibodies included a permeabilization treatment with
PBS-0.05% Triton X-100 as previously reported (Carrasco-Marín
et al., 2012). Confocal microscopy imaging was performed with
a Nikon A1R confocal microscope equipped with the laser lines:
405, 488, 514, 561, 638 nm using 60× Plan Apochromat VC 1.4
NA oil objective.
PEPTIDES
We used the following peptides, GAPDH1−22, LLO1−99, and
LLO189−201, the latter includes all MHC-II epitopes of LLO
reported for IAb mouse haplotype, LLO189−200 and LLO190−201
(Ziegler and Unanue, 1981; Sijts et al., 1996; Geginat et al., 2001;
Skoberne and Geginat, 2002; Carrero et al., 2012). All peptides
were synthesized and purified by F. Roncal (CNB. CSIC. Madrid)
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after HPLC andMass Spectrometry using aMALDI-TOF Reflex™
IV Bruker (Bruker Daltonics, Bremen, Germany) mass spectrom-
eter. Peptide synthesis showed purity >95% after HPLC and mass
spectrometry.
PREPARATION OF PEPTIDE-PULSED BMDMs OR DCs
Differentiated and mature BMDMs or DCs were cultured in
DMEM complete medium at a concentration of 2 × 106 cells/ml
and pulsed with 5μMLLO91−99, LLO189−201, or GAPDH1−22 for
24 h. Cells were washed twice in Hank’s Balanced Salt Solution
(HBSS), detached with cell scrapers and counted.
VACCINATION PROTOCOLS
Differentiated and matured BMDMs or DCs were cultured in
six-well plates at 2 × 106 cells/ml and incubated with differ-
ent peptides, as described in the previous section. For BMDMs
or DCs loaded with LM-WT vaccines, we infected cells with
L. monocytogenes as above for 0 h. Cells were washed and cul-
tured in DMEM–2% FCS and 20μg/ml gentamicin for 24 h.
Cells were washed with HBSS, detached with cell scrapers,
washed three times, counted, and cell pellets were resuspended
at 1 × 106 cells/ml in DMEM–20μg/ml gentamicin. Different
BMDM or DC vaccine vectors (5 × 105 cells/mice) were inocu-
lated in the peritoneal cavity of mice (n = 5) for 7 days or were
non-vaccinated (NV). In same controls, vaccinations were per-
formed with peptides in solution (5μM) administrated similar
to DC vaccines. All mice were inoculated with 103 CFU L. mono-
cytogenes i.p. for an additional 3 days. The vaccination timing
followed similar protocols reported for studies using L. mono-
cytogenes as a vaccine (Lauer et al., 2008; Rodriguez-Del Rio
et al., 2011; Carrasco-Marín et al., 2012; Kono et al., 2012). Mice
were bled before sacrifice and serum stored at −80◦C to measure
cytokines by FACS analysis. Spleens and livers were homogenized
and CFUs counted in homogenates.
FACS ANALYSIS OF BMDMs, DCs, AND CYTOKINE MEASUREMENTS
BMDMs or DCs were cell surface labeled with antibodies against
the following markers: CD11b (for macrophages), CD11c (for
DCs), F4/80 (for activated phagocytes), CD80 (for mature DCs),
CD86 (for mature DCs) or IAb (MHC-II for C57BL/6 mice) and
analyzed by FACS. Cytokines of vaccinated and NV mice were
quantified by using the CBA kit (BectonDickinson, Palo Alto, CA,
USA). Samples were performed in triplicate and the results are
the mean ± SD of two separate experiments. ANOVA was used
for statistics with the cytokine measurements. Data were analyzed
using the FlowJo software (Treestar, Ashland, OR).
FACS ANALYSIS OF SPLEENS
We used FACS analysis for cell surface labeling of spleen cells (105
cells), using monoclonal antibodies FITC or APC-labeled (BD
Biosciences, San Jose, CA, USA) against CD4 or CD8. Peptides
used were LLO1−99, LLO189−201, or GAPDH1−22. For measur-
ing intracellular IFN-γ, spleen cells were plated into 96-well
round-bottom plates (5 × 106 cells/ml) and stimulated with each
of the LLO91−99, LLO189−201, or GAPDH1−22 peptides inde-
pendently (10−5 M each peptide) for 5 h in the presence of
brefeldin A (intracellular cytokine staining), as described previ-
ously (Bahjat et al., 2008; Lauer et al., 2008; Rodriguez-Del Rio
et al., 2011; Carrasco-Marín et al., 2012). Stimulated cells were
surface stained for CD4 and CD8 and then fixed and permeabi-
lized using a cytofix/cytoperm kit to measure intracellular IFN-γ
(BD Biosciences). Samples were acquired using a FACSCanto flow
cytometer (BD Biosciencies). Data were gated to include exclu-
sively CD4+ or CD8+ events, and the percentages of these cells
expressing IFN-γ were determined according with the manu-
facturer’s recommendations. Results of LLO-peptide-stimulated
splenocytes were corrected according to the percentages of total
CD4+ and CD8+ cells. Data were analyzed using FlowJo soft-
ware (Treestar, Ashland, OR, USA). To confirm the frequency of
LLO91−99- or GAPDH1−22-specific CD8 T cells producing IFN-γ,
we used recombinant soluble dimeric mouse H-2Kb:Ig fusion
protein following the instructions of the manufacturer (DimerX
I; BD Bioscience). LLO91−99 or GAPDH1−22 peptides (40μM)
were preincubated with H-2Kb:Ig (1μM) in PBS, at 37◦C for
16 h and incubated with the staining cocktail mix containing PE-
conjugated A85-1 mouse monoclonal antibody (BD Biosciences)
for 1 h at room temperature. Splenocytes (2 × 107 cells/ml) were
incubated with IFN-γ and CD8 antibodies and the staining
cocktail mix described above for 10min at 4◦C. Percentages of
CD8+ gated cells were expressed as the mean ± SD of triplicates
(P < 0.05). Data were analyzed using FlowJo software.
STATISTICAL ANALYSIS
For statistical analysis, the Student’s t-test was applied. ANOVA
analysis was applied also for cytokine measurement. P ≤ 0.05 was
considered significant. GraphPad software was used for graphic
presentation.
ETHICS STATEMENT
This study was carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory
Animals of the Spanish Ministry of Science, Research and
Innovation. The Committee on the Ethics of Animal Experiments
of the University of Cantabria approved this protocol (Permit
Number: 2012/06) that follows the Spanish legislation (RD
1201/2005). All surgery was performed under sodium pentobar-
bital anaesthesia, and all efforts were made to minimize suffering.
RESULTS
PREPARATION OF BMDM AND DC VACCINE VECTORS INFECTED
WITH LM
To use BMDMs and DCs as vectors loaded with pathogenic
L. monocytogenes, we first discarded any differences in BMDM
and DC phagocytic parameters, balancing their differentia-
tion and maturation states. We differentiated both cells with
their corresponding growth factors, M-CSF or GM-CSF and
checked their maturation states. All BMDM preparations
were CD11b+F4/80lowIAb+CD45+ with 90% double-positive
CD11b+CD45+ and 60% positive IAb+ cells by FACS. DC prepa-
rations were CD11c+F4/80lowCD11blowIAb+ with 95% positive
CD11c+ and 70% positive IAb+ cells.
We examined whether L. monocytogeneswas able to infect both
cells with similar kinetics. Infection of BMDMs with pathogenic
L. monocytogenes (LM-WT) showed a characteristic exponential
proliferation of 4 h duration that ended in a plateau phase of
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growth at 16 h post-infection. However, LM-WT growth in DCs
remained exponential even at 16 h post-infection (Figure 1A,
black circles). Listericidal phagocytes degraded L. monocytogenes
within the phagosomal environment.
To compare the listericidal abilities of both BMDMs and DCs,
we used a L. monocytogenes hly-deficient strain (LM-LLO) with
a known gene deletion that rendered it unable to escape from
phagosomes. BMDMs and DCs had similar listericidal activity,
FIGURE 1 | BMDM and DC vaccines infected with different
L. monocytogenes strains. (A) Kinetic analysis of murine BMDMs and
DCs infected with LM-WT or LM-LLO. Results are expressed as CFU
(mean ± SD) obtained with triplicate samples from three independent
experiments (main differences are observed between LM-WT and
LM-LLO results, P < 0.05). (B) BMDMs or DCs were infected with
LM-WT or LM-LLO (10:1 ratio of bacteria: cells) for 2 h or were
non-infected (NI), detached from plates, washed several times, and
surface stained with the following FITC- or PE-labeled antibodies:
CD45–FITC, F4/80–PE, CD11b–APC, CD11c–PE, or anti-IAb–APC. Samples
were acquired using a FACSCanto flow cytometer and percentages of
positive cells for each antibody are shown. Results are expressed as the
mean ± SD of triplicate samples (P < 0.05). (C) Images correspond to
confocal microscopy projections of BMDMs or DCs infected with
GFP-LM (green channel), anti-MHC-II antibodies that label the
antigen-processing compartments (Y3P biotinylated antibody followed by
goat anti-mouse TRITC labeled) (red channel) and DNA (blue channel).
Colocalization of GFP-LM and MHC-II (yellow fluorescence) is observed in
BMDMs and DCs images. All BMDM preparations were
CD11b+CD45+F4/80highMHC-IIhigh, reflecting their macrophage origin and
purity and DC preparations were CD11c+F4/80highCD11blowMHC-IIhigh,
reflecting their DC origin and purity.
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because LM-LLO strain did not replicate in BMDMs or DCs
(Figure 1A, white circles). Activation of phagocytes seems to
be a prerequisite to trigger a powerful and protective immune
response against L. monocytogenes. High percentages of posi-
tive MHC-II+ and F4/80+ cells are characteristics of activated
phagocytes. Infection with LM-WT increased the number of pos-
itive cells for MHC-II and F4/80 in BMDMs and DCs, showing
95–100% positive IAb cells in both cell types (Figure 1B, white
bars). However, the number of positive cells of markers not
involved in activation such as CD11b for BMDMs or CD11c for
DCs was not increased but diminished (Figure 1B, black bars).
LM-LLO strain infection caused nomodification in the number
of positive MHC-II+ or F4/80+ BMDMs or DCs (Figure 1B, gray
bars). In summary, the phagocytic features of BMDMs and DCs
infected with LM-WT appeared similar but clearly different than
when these cells were infected with LM-LLO. This prompted us
to discard the use of LM-LLO mutants in cellular vaccination.
We measured the ability of phagosomes to transform into
antigen-processing compartments or MIIC using a method that
colocalized GFP-LM-WT with MHC-II molecules in BMDMs
and DCs infected with L. monocytogenes (Carrasco-Marín
et al., 2011). Analysis of confocal images indicated significant
colocalization of GFP-LM with MHC-II molecules in BMDMs
and DCs (yellow fluorescence in Figure 1C). CD11b or CD11c
molecules, not involved in antigen presentation and in the case
of CD11c with a preferential surface pattern, did not colocalize
with GFP-LM (data not shown). BMDMs and DCs showed
similar GFP-LM colocalization with MHC-II molecules, 70 and
72% rates of colocalization, respectively. In summary, BMDMs
infected with LM-WT showed similar phagocytic, activation and
antigen processing features as DCs.
SELECTION OF L. MONOCYTOGENES ANTIGENS TO EVALUATE
PRIMARY T CELL RESPONSES AFTER VACCINATION WITH BMDMs
AND DCs
LLO appears as the immunodominant antigen that elicits specific
T cell responses in listeriosis (Geginat et al., 2001; Skoberne
and Geginat, 2002; Pamer, 2004; Bruder et al., 2005; Carrero
et al., 2012). Studies from our group have also characterized a
novel L. monocytogenes antigen, GAPDH that generates peptide-
restricted antibodies in the absence of adjuvants, suggesting the
induction of strong T cell responses (Álvarez-Domínguez et al.,
2008). First, we verified that LLO and GAPDH generated specific
T cells responses with similar efficiencies. Macrophages and DCs
are the main APCs in lymph nodes able to stimulate T cells. We
immunized the hind footpads of mice with a bacterial lysate
(LM-lysate) in the absence of adjuvants as described previously
(Mohamed et al., 2012) and recovered the popliteal lymph nodes
to evaluate specific T cell responses to different antigens in vitro.
T cell responses were dose dependent, similar for purified LLO,
GAPDH or L. monocytogenes lysates, and had a significant peak
at 50μM concentrations (Figure 2B). Therefore, immunization
with bacterial lysates generated LLO- and GAPDH-specific T
cells in similar ranges. These results strongly suggested that
macrophages and DCs in vivo processed LLO and GAPDH
with similar efficiencies, since their T cell responses were com-
parable or even slightly enhanced with GAPDH (gray bars in
Figure 2A). We also confirmed antigen processing efficiency after
immunoprecipitation of MHC-II molecules from total mem-
branes of BMDM and DCs infected with LM-WT. We recovered
LLO and GAPDH bound forms to MHC-II molecules as previ-
ously reported (Carrasco-Marín et al., 2012) (data not shown).
We compared the surface expression patterns of BMDMs
or DCs loaded with purified LLO or GAPDH, or after infec-
tion with LM-WT. We prepared BMDMs and DCs followed
by infection with LM-WT (bacteria: cells ratio, 10:1) (BMDM-
LM-WT or DC-LM-WT) or loaded with 50μM purified LLO
(BMDM-LLO or DC-LLO) or GAPDH (BMDM-GAPDH or DC-
GAPDH) for 16 h. BMDM-LLO, DC-LLO, BMDM-GAPDH, and
DC-GAPDH showed an increase in the percentages of MHC-
II+ positive cells, similar to the enhancement observed with
DC-LM-WT. However, DC-LLO or DC-GAPDH caused no sig-
nificant modification in the numbers of positive CD11b+ or
CD11c+ cells (Table 1). These data suggest that DC-LM-WT,
DC-LLO, and DC-GAPDH showed similar percentages of pos-
itive MHC-II+ cells that might correspond to mature DCs and
not to immature DC. Incubation of DC with certain pep-
tides was previously reported to cause similar DC maturation
(Pion et al., 2010; Kono et al., 2012).
Widely characterized LLO immunodominant CD8+ and
CD4+ epitopes are: CD8+-restricted LLO91−99 peptide that binds
to MHC-I molecules (Kb, Kd, or Ld) and CD4+-restricted
LLO189−201 peptide that binds to MHC-II molecules (IAb)
(Geginat et al., 2001; Skoberne and Geginat, 2002; Bruder et al.,
2005). No information on GAPDH immunodominant CD4+ or
CD8+ epitopes is available, therefore, we performed prediction
analysis on the binding abilities of GAPDH1−22 to MHC-I or
MHC-II molecules using a prediction method with the IEDB
analysis resource Consensus tool (Kim et al., 2012), which com-
bines predictions from ANN (Nielsen et al., 2003; Lundegaard
et al., 2008), SMM (Peters and Sette, 2005), and Comblib (Sidney
et al., 2008). We also included in this analysis LLO91−99 and
LLO189−201 peptides because these epitopes were eluted from
MHC-I and MHC-II molecules, respectively, and their bind-
ing affinities are known (Geginat et al., 2001; Skoberne and
Geginat, 2002) (Table 2). IEDB analysis predicted that good
binders showed percentile ranks <10, while weak binders showed
percentile ranks <100. GAPDH1−22 peptide was a strong binder
toMHC-Imolecules, similar to LLO91−99. The following GAPDH
sequences showed the highest affinities, GAPDH5−15 with a 1.60
percentile rank and GAPDH8−18 with a 2.3 percentile rank,
compared with a 1.80 percentile rank for LLO91−99 (Table 2,
MHC-I binding values). With regards to binding to MHC-II
molecules, it seems that GAPDH1−22 peptide and LLO189−201
were weak binders, with percentile ranks of 74. The GAPDH
sequence with the lower percentile ranks was GAPDH4−18
with 69.15. GAPDH8−22 showed percentile ranks similar to
LLO189−201 (Table 2, MHC-II binding values). When we applied
these data to the bioinformatics modeling of GAPDH1−22 and
LLO 3D structures (Figures 2C,D), LLO189−201 presented an α-
helix type 3D structure, while LLO91−99 peptide had a loop
structure (Figure 2D). GAPDH5−15 also appeared as a loop
3D structure (Figure 2C, pink in 3D model) and GAPDH8−22
showed an α-helix 3D structure (Figure 2C, yellow in 3Dmodel).
The theoretical 3D predictive model for Listeria monocytogenes
GAPDHwas produced using the Automated Comparative Protein
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FIGURE 2 | Selection of L. monocytogenes antigens to evaluate
primary T cell responses after vaccination with BMDMs and DCs.
(A) Thirty micrograms of total membranes of BMDMs or DCs infected
with L. monocytogenes was immunoprecipitated with mouse
anti-MHC-II, and subjected to western blotting with rabbit anti-LLO
(upper lanes) or rabbit anti-GAPDH1−22 (lower lanes). NI lanes
correspond to non-infected BMDMs or DCs. (B) T cell proliferation of
homogenates of popliteal lymph nodes after hind foot pad inoculation
with 30μg LM-lysate. Cells were stimulated with LLO, GAPDH, or
LM-lysate. Results show [3H]-thymidine incorporation in triplicate
samples of T cells. (C) 3D model of GAPD1−22 peptide showing the
MHC-I binding sequences in pink and the MHC-II binding sequences in
yellow. (D) 3D structure of LLO showing the MHC-I and MHC-II
epitopes in the C57BL/6 mouse model.
Modeling Server SWISS-MODEL available at: (http://www.
expasy.ch/swissmod/SWISS-MODEL.html). Therefore, it seems
that GAPDH1−22 peptide might contain at least two MHC-I
binding sequences as well as two MHC-II binding sequences in
the C57BL/6 mouse model. Taken together, these results indi-
cate that LLO and GAPDH, as well as their epitopes, are good
candidates to include in cellular vaccine designs against listeriosis.
COMPARISON OF DIFFERENT BMDM AND DC VACCINE VECTORS FOR
PROTECTION AGAINST LISTERIOSIS
As a first approach using cellular vaccine vectors against listeriosis,
we prepared different BMDM and DC vaccine vectors contain-
ing LM-WT, LLO, or GAPDH, and used them in vaccination
protocols against an L. monocytogenes challenge of 5 × 103 bacte-
ria/mice (n = 5), inoculated for 3 days. We also tested the in vitro
cytotoxicity of these vaccine vectors using a hemolysis assay with
sheep-red blood cells, SRBC. Although BMDMs infected with
LM-WT showed a good protection range, they also showed a
high level of hemolysis (∼70%). Two of five mice vaccinated died
and showed hemolyzed livers (data not shown). BMDMs loaded
Table 1 | Surface markers of different BMDM and DC vaccine vectors.
BMDM1 DC
CD11b MHC-II CD11c MHC-II
NI 87 ± 1.5 62 ± 1.2 87 ± 1.3 72 ± 1.3
LM-WT 73 ± 1.3 90 ± 2.0 98 ± 1.5 92 ± 1.4
LLO 70 ± 1.2 92 ± 1.9 87 ± 1.6 92 ± 1.5
GAPDH 73 ± 1.3 92 ± 1.8 89 ± 1.7 92 ± 1.6
BMDMs and DCs were infected with LM-WT (10:1 ratio of bacteria: cells) or
incubated with 50 μg/ml purified LLO or GAPDH for 16 h, detached from the
plates, washed several times, and surface stained with the following FITC- or
PE-labeled antibodies: CD11b–FITC, CD11c–PE, anti-IAb–APC. Samples were
acquired using FACSCanto flow cytometer and percentages of positive cells for
each antibody are shown. Results are expressed as the mean ± SD of triplicate
samples. (1P < 0.05).
with LLO showed ∼50% protection but also 30% hemolysis, and
one of five vaccinated mice died and presented with a hemolyzed
liver (Figure 3A, gray bars). BMDMs loaded with GAPDH lacked
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Table 2 | MHC-I and MHC-II binding force predictions for LLO and
GAPDH epitopes.
MHC-I binding MHC-I allele Percentile rank Sequence
LLO91−99 H-2-Kd 1.8* Complete (GB)
H-2-Ld 38.3
H-2-Kb 75.1
GAPDH1−22 H-2-Kb 1.6* 5–15*
H-2-Ld 2.3 8–18
H-2-Kd 4.7 8–16
MHC-II binding MHC-II allele Percentile rank Sequence
LLO190−201 H-2-IAb 74.3* Complete (WB)
GAPDH1−22 H-2-IAb 69.15* 4–18*
H-2-IAb 70.23 5–19
H-2-IAb 70.91 2–16
H-2-IAb 71.11 3–17
H-2-IAb 74.95* 8–22*
H-2-IAb 75.61 7–21
H-2-IAb 75.72 1–15
Predictions of binding of peptides to MHC molecules performed with the
IEDB analysis source Consensus tool. The lower the percentile ranks obtained,
the better the binders. GAPDH1-22 peptide was compared to the predictions
of LLO91-99 binding to MHC-I molecules and LLO189-201 binding to MHC-II
molecules.
*Comparative peptide sequence with similar binding percentiles as LLO
peptides. GB, good binder; WB, weak binder.
cytotoxicity but their protection was low (∼40%). We obtained
the highest protection and the lowest cytotoxicity using DC-LLO
or DC-GAPDH with 90–95% protection. DCs infected with LM-
WT also showed good protection in the range of 65–70%, with
no cytotoxicity (Figure 3A, compare black and gray bars, respec-
tively). These results revealed that BMDMs were unsafe vaccine
vectors against listeriosis, because they resulted in high cytotoxi-
city, either containing LM-WT or purified LLO. DCs seemed to
be the safest vaccine vectors, conferring the highest protection
against listeriosis.
To examine whether DCs loaded with LLO or GAPDH
epitopes might also confer protection against listeriosis, we
prepared DC vaccines loaded with peptides, DC-LLO91−99,
DC-LLO189−201 or DC-GAPDH1−22, and compared them for
protection with DCs loaded with an L. monocytogenes lysate (DC-
LM lysate). Peptides in solution administrated as DC vaccines
showed no protection at all (data not shown). As shown in
Figure 3B (left plot), DC-GAPDH1−22 showed the highest pro-
tection (∼99%), followed by DC-LLO91−99 (∼94%) (Figure 3B,
GAPDH1−22/DC and LLO91−99/DC bars in left plot). However,
DC-LLO189−201 conferred little protection (∼5%), comparable
to DC empty vaccine vectors or mice inoculated with saline
(Figure 3B, NV-DC bars in left plot). NV mice showed charac-
teristic features of listeriosis, such as granulomatous lesions in
the liver and splenomegalia (Figure 3B, NV-DC upper image).
Vaccinated mice with DC-GAPDH1−22 showed a clear reduction
in liver granulomatous lesions and presented normal size spleens
(Figure 3B, DC-GAPDH1−22 image), similar to vaccination with
DC-LLO91−99 (Kono et al., 2012). To note that positive selection
of differentiated DCs with anti-mouse CD11c-coated magnetic
beads and MACSTM separation columns did not give better
protection results than our method (data shown in legend of
Figure 3).
Effective DCs vaccine vectors present high percentages of pos-
itive CD80+ or CD86+ cells as classical DC activation markers
as previously reported for DCs incubated with certain peptides
(Pion et al., 2010). Therefore, we evaluated whether the high effi-
ciency of DC-LLO91−99 or DC-GAPDH1−22 might correspond
with high numbers of positive cells for these DC activation mark-
ers. As it is shown in Figure 3B (right plot), only DC-LLO91−99
or DC-GAPDH1−22 showed an increase in the number of positive
CD80+ or CD86+ cells, similar to percentages obtained with DCs
loaded with lipopolysaccharide, LPS (DC-LPS), used as a posi-
tive control. We also observed that DC-GAPDH1−22 showed a
decrease in the percentages of positive CD11c+ cells, similar to
the pattern of DC-LPS, while DC-LLO91−99 showed no modifi-
cation on the percentages of positive CD11c+ cells. A decrease
in the number of positive CD11c+ cells in DCs appears linked
to polarized DCs, as in the case of LPS-loaded DCs (Kono et al.,
2012).
We confirmed whether the protection capacity of DC vac-
cine vectors was linked to Th1 cytokine production. As shown in
Figure 3C, DC vaccine vectors conferring protection against lis-
teriosis, such as DC-LM-WT, DC-LLO91−99 or DC-GAPDH1−22,
produced high levels of interleukin (IL)-2 and IFN-γ (570–589 ±
0.9 pg/ml, andNVmice basal levels, 0.5± 0.02 pg/ml) and signifi-
cant levels of monocyte chemotactic protein (MCP)-1 and tumor
necrosis factor (TNF)-α. Mice vaccinated with DC-GAPDH1−22
produced significantly more IL-12 than those vaccinated with
DC-LLO91−99 did. Production of IL-6 was significantly reduced
after vaccination with DC-LLO91−99 or DC-GAPDH1−22, indi-
cating that the classical acute inflammation in listeriosis was
avoided with vaccination. Therefore, the vaccination efficiency
of DC-GAPDH1−22 was related to high production of IL-12, as
well as significant levels of other Th1 cytokines such as IFN-γ,
MCP-1, and TNF-α. We did not observe any production of IL-10
in DC-vaccinated mice.
Vaccine efficiency is also linked to DC ability to expand the
immune response, stimulating different T cells, both CD4 and
CD8 subsets. Therefore, we analyzed the spleens of mice vacci-
nated with DC-LLO91−99, DC-LLO189−201, or DC-GAPDH1−22
for production of a primary T cell response. We observed 1.2 ±
0.05% positive CD8+-restricted LLO91−99 cells and IFN-γ pro-
ducers after vaccination with DC–LLO91−99. We also observed
0.75± 0.02% positive CD4+-restricted LLO189−201 cells and IFN-
γ producers after vaccination with DC-LLO189−201. We observed
1.23 ± 0.04% CD4+-restricted GAPDH1−22 cells and IFN-γ
producers and 1.81 ± 0.1% CD8+-restricted GAPDH1−22 cells
and IFN-γ producers (Figure 3D). These results suggested that
although vaccination with DC-LLO189−201 induced a primary
and specific CD4+ T cell response, these vaccines did not confer
any protection against listeriosis. Vaccination with DC-LLO91−99
induced a strong and specific CD8+ T cell response and conferred
protection. Vaccination with DC-GAPDH1−22 induced specific
CD4+ and CD8+ T cell responses and was highly protective.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org February 2014 | Volume 4 | Article 22 | 7
Calderón-González et al. GAPDH1−22 peptide dendritic vaccines efficiency
FIGURE 3 | Comparison of different BMDM and DC vaccine vectors
for protection against listeriosis. (A) C57BL/6 mice were vaccinated
i.p. or not (NV) for 7 days with different BMDM or DC vaccine vectors
(BMDM-LM-WT, BMDM-LLO, BMDC-LM-WT, BMDC-LLO, and
BMDC-GAPDH) (1 × 106 cells) (n = 5 mice/vaccine vector) and
challenged i.p. with 5 × 103 CFU LM-WT for 3 days. Results of spleens
homogenates are mean ± SD of three different experiments (P < 0.01)
(black bars in figure and left scale legend). Same vaccine vectors were
incubated in vitro with SRBC (0.5% solution). Hemolytic units were
defined as the dilution of the sample that caused 50% hemoglobin
release from 200ml of 0.5% SRBC. Controls were established for 0%
hemolysis using empty DCs and for 100% hemolysis by incubating
SRBC with distilled water. (B) C57BL/6 mice were vaccinated i.p. or
not with empty DCs (DC-Ø) or with saline (NV) using the vaccine
vectors: DC-LM lysate, DC-GAPDH1−22, DC-LLO189−201, DC-LLO91−99.
We also vaccinated with the following control vectors: DC-LMWT,
DC-LPS-LLO91−99, and DC-LPS-GAPDH1−22 protection results were as
follows: 70, 92, and 98%. In several samples, positive selection of DC
was performed with anti-mouse CD11c-coated magnetic beads and
MACSTM separation columns, protection results of DC-LLO91−99 and
DC-GAPDH1−22 after positive selection were as follows, 90 and 98%,
respectively. Left plot corresponds to results of spleens homogenates
that are the mean ± SD of three different experiments (P < 0.05).
Surface expression of different markers was analyzed by FACS in the
prepared DC vaccine vectors. Samples were acquired using FACSCanto
flow cytometer and percentages of positive cells for each antibody are
shown. Results are expressed as the mean ± SD of triplicate samples
(P < 0.05). (C) Cytokines were measured in serum from vaccinated and
NV mice (DC-Ø) from (B). We also included another DC vaccine vector
(DC-LPS) as a positive control. Levels of proinflammatory cytokines
(MCP-1, TNF-α, IFN-γ, IL-6, IL-12, or IL-10) were analyzed by using the
CBA kit (Becton Dickinson) and flow cytometry. Results were expressed
as cytokine concentration (pg/ml of mean ± SD, P < 0.05). IL-12
concentration for DC-Ø vaccination was 8 ± 0.03 pg/ml and for DC-LPS,
19 ± 0.2 pg/ml. IFN-γ concentrations of samples were as follows:
DC-LLO91−99 (389 ± 12 pg/ml), DC-GAPDH1−22 (425 ± 11pg/ml),
DC-LMWT (178 ± 10pg/ml), DC-LPS (200 ± 0.3 pg/ml). (D) Spleen cells
obtained from homogenates after vaccination were stimulated for 5 h
with GAPDH1−22in the presence of brefeldin A for intracellular cytokine
staining. GAPDH-peptide-stimulated spleen cell surface was stained for
CD4 or CD8 and fixed and permeabilized using a cytofix/cytoperm kit.
Stimulated cells were surface stained for CD4 or CD8 using anti-CD4+
FITC-labeled or anti-CD8+ APC-labeled and data gated to include
exclusively CD4+ or CD8+ events, R2, and R3 gates, respectively. Flow
histograms show the percentages of GAPDH1−22/CD4+ and IFN-γ
producers (lower left) and GAPDH1−22/CD8+ and IFN-γ producers (lower
right) (R2 and R3 gates). Experiments were performed in triplicate and
results are expressed as the mean ± SD (P < 0.05).
We confirmed the frequency of LLO91−99-specific and
GAPDH1−22-specific CD8+ T cells using H2-Kb-LLO91−99 or
H2-Kb-GAPDH1−22 dimers by flow cytometry after vaccination
with DC-LM-WT, DC-LLO91−99or DC-GAPDH1−22. As shown
in Table 3, the occurrence of LLO91−99-specific CD8+ cells pro-
ducing IFN-γ after vaccination with DC-LLO91−99 was 1.22%
of positive gated cells, which was higher than the frequency
observed with DC-LM-WT (0.48%) (P < 0.05). The occurrence
of GAPDH1−22-specific CD8+ cells was 4.02% of positive gated
cells; which was higher than the frequency one observed with
DC-LM-WT-vaccinated mice (1.53%). Therefore, primary T cell
responses highlighted the role of L. monocytogenes-specific CD8+
Frontiers in Cellular and Infection Microbiology www.frontiersin.org February 2014 | Volume 4 | Article 22 | 8
Calderón-González et al. GAPDH1−22 peptide dendritic vaccines efficiency
Table 3 | Frequencies of LLO91−99- and GAPDH1−22-specific CD8+ T cells induced by DC vaccines.
Vaccination type % Total % Gated % Total % Gated
dimer-CD8/LLO91-99 dimer-CD8/LLO91-99 dimer-CD8/GAPDH1-22 dimer-CD8/GAPDH1-22
DC-LM-WT 0.05 ± 0.001 0.48 ± 0.01 0.05 ± 0.002 1.53 ± 0.02
DC-LLO91−99 0.06 ± 0.001 1.22 ± 0.02 NA NA
DC-GAPDH1−22 NA NA 0.16 ± 0.001 4.02 ± 0.03
Splenocytes from vaccinated mice were incubated with recombinant dimeric H-2Kb:Ig fusion protein loaded with LLO91-99 or GAPDH1-22 peptides. The staining
cocktail contained the dimeric fusion protein loaded with the peptides, CD8 and IFN-γ antibodies. CD8+ cells were gated for anti-IFN-γ staining (% Gated dimer-CD8)
to calculate the frequencies of CD8+-LLO91-99 or CD8+-GAPDH1-22 restricted cells and IFN-γ producers. p < 0.05.
T cells to confer significant protection against listeriosis, while
CD4+ T cells seemed to participate less in protection.
DISCUSSION
Recently, cell-based vaccines have received considerable impe-
tus following their success against infectious diseases and can-
cer (Starks et al., 2004; Kim et al., 2009; Pion et al., 2010;
Singh et al., 2011; Kono et al., 2012; Martirosyan et al., 2012;
Matsumura et al., 2013; Quispe-Tintaya et al., 2013; Vacas-
Cordoba et al., 2013). In the case of listeriosis vaccination, the
emphasis has been on recombinant vaccines using live attenuated
pathogens, metabolically active but non-viable bacteria or non-
pathogenic bacteria harboring virulence gene clusters, although
some of them do not trigger strong innate immune responses
and require adjuvants (Brockstedt et al., 2005; Bruhn et al.,
2007; Mohamed et al., 2012). These recombinant vaccines might
also present safety concerns because live vaccines if administered
to immunocompromised individuals might cause cytotoxicity.
However, cellular vaccines such as BMDMs or DCs, or subcel-
lular vectors such as endosomes or phagosomes appear to be
safer candidates to harbor L. monocytogenes antigens because
the vaccinated individuals are not directly exposed to live bac-
teria (Sashinami et al., 2003; Rodriguez-Del Rio et al., 2011;
Carrasco-Marín et al., 2012; Kono et al., 2012). Moreover, high
phagocytic abilities and induction of strong innate and spe-
cific immune responses are features that make cellular vaccines
attractive.
We have attempted to design novel cell-based vaccines for
listeriosis lacking cytotoxicity and pathogenicity and showing
high protective activity. For this purpose, we chose BMDMs
and DCs as vaccine vectors against L. monocytogenes. In this
regard, the features of the cellular vaccines conferring success-
ful protection against listeriosis were high phagocytic activ-
ity and good antigen processing. We observed that BMDMs
and DCs infected with LM-WT shared equivalent listericidal
features, activation patterns, and antigen processing compe-
tency. Therefore, BMDMs and DCs showed similar L. mono-
cytogenes growth kinetics and degradation of the hly-deficient
mutant LM-LLO. BMDMs were CD11b+F4/80highMHC-IIhigh
cells and DCs were CD11c+F4/80highCD11blowMHC-IIhigh cells.
BMDMs and DCs transformed L. monocytogenes phagosomes
into MIIC compartments with similar ratios, showing 70–72%
colocalization of GFP-LMwithMHC-IImolecules. Unexpectedly,
protection and cytotoxicity of these vaccine vectors were dif-
ferent. BMDMs showed protection ratios lower than those of
DCs and high cytotoxicity measured in vitro by SRBC hemol-
ysis and in vivo by examining death in mice. Recently, LLO
immunogenicity and cytotoxicity were dissociated, indicating
that LLO was available in L. monocytogenes infection (Carrero
et al., 2012). It is possible that different amounts of LLO were
available for BMDMs or DCs or different surface receptors,
explaining their differences in cytotoxicity. Therefore, we selected
DCs as the vectors showing features of safe vaccines. We also
searched for the most suitable L. monocytogenes antigen that
triggered protective Th1 responses. Although CD8+ T cells recog-
nize several epitopes, immunodominant CD8 epitopes are eluted
from MHC-I molecules and associate with effector functions.
Pathogen-specific CD8+ T cells play a major role in protection
against listeriosis, but also pathogen-specific CD4+ T cells effi-
ciently collaborate in conferring protective immunity (Skoberne
and Geginat, 2002; Pamer, 2004; Nagata and Koide, 2010). To
date, LLO has been revealed as the immunodominant anti-
gen in listeriosis and the CD8+-specific LLO91−99 epitope is
the major epitope eluted from MHC-I molecules, which con-
fers protection (Kono et al., 2012). However, the CD4+-specific
LLO189−201 epitope also confers protection against listeriosis and
appears as the major epitope eluted from MHC-II molecules
(Geginat et al., 2001; Skoberne and Geginat, 2002). In this
study, we presented the abilities of a novel L. monocytogenes
antigen, GAPDH, which is a powerful antigen that triggers T
cell responses in vivo (Álvarez-Domínguez et al., 2008 and this
study in the hind foot pads). We also described the features
of the GAPDH1−22 peptide that contained CD8+-specific and
CD4+-specific epitopes that were combined in DC vaccine vec-
tors; DC-GAPDH1−22, confers protection against listeriosis with
higher ratios than DC-LLO91−99 vectors. Several characteristics
of GAPDH1−22 peptide make this long epitope attractive for
vaccination purposes. GAPDH1−22 peptide was a strong binder
to MHC-I and a weak binder to MHC-II molecules. This pep-
tide contains at least two strong binding sequences to MHC-I
molecules similar to LLO91−99 epitope, sequences GAPDH5−15
and GAPDH8−18. This peptide also shows two weak binding
sequences to MHC-II molecules similar to LLO189−201 epitope,
sequences GAPDH4−18 and GAPDH8−22. According to the 3D
structure modeling, GAPDH5−15 is localized in a loop sim-
ilar to the 3D loop structure of LLO91−99 and GAPDH8−22
in the α-helix structure that is shared by most MHC-II bind-
ing sequences, including LLO189−201. Combination of MHC-I
and MHC-II binding epitopes might explain the ability of DC-
GAPDH1−22 vaccine vector to confer higher protection against
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listeriosis than DC-LLO91−99 vaccine vector can. It can also
explain why DC-GAPDH1−22 vaccine vector elicited greater
primary T cell responses since it can elicit both, CD4+ and
CD8+-restricted responses. However, DC-LLO189−201 and DC-
LLO91−99 vaccine vectors elicit only CD4+ or CD8+-restricted
responses, respectively. Moreover, these results are also in agree-
ment with studies indicating that L. monocytogenes-specific CD4+
T cells played a role in protection against listeriosis, probably
collaborating with immunodominant epitope-specific CD8+ T
cells (Nagata and Koide, 2010). DC-GAPDH1−22 vaccine vectors
produced higher IL-12 levels and frequencies of GADPH1−22-
restricted CD8+ T cells than the induction observed with the
single CD8+ epitope DC-LLO91−99 vaccine vector. Production
of IL-12 is related to anti-Listeria responses and with vaccine
success (Kono et al., 2012; Lee et al., 2013). Therefore, it seems
that DC designs containing CD8+ and CD4+ epitopes such as
DC-GAPDH1−22 are effective vaccine vectors. Production of Th1
cytokines MCP-1, TNF-α and IFN-γ and lack of production of
Th2 cytokines such as IL-6 and IL-10, which are responsible for
exaggerated inflammatory reactions and putative autoimmune
responses in listeriosis, are features that are also relevant for pro-
tective DC vaccine vectors (Kono et al., 2012; Vacas-Cordoba
et al., 2013).
In summary, the present study revealed a novel DC design,
DC-GAPDH1−22, which confers greater protection against liste-
riosis than the previously described DC design, DC-LLO91−99.
We conclude that DC-GAPDH1−22, which combines several
CD4+ and CD8+ epitopes in a single vaccine vector, shows
greater protection against listeriosis, because this DC vaccine
increases the magnitude of primary T cell responses, the per-
centage of GAPDH1−22-restricted CD8+ T cells, and the levels
of IL-12. Also, the phenotype of DC-GAPDH1−22 vaccine vec-
tor with higher expression of the maturation markers, CD80
and CD86, characteristic of polarized and IL-12-producing
DCs (Kono et al., 2012) might also contribute to protective
efficacy.
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